Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OTX-DP (Dextenza) for Allergic Conjunctivitis
NCT04050865Phase 3Completed
- Sponsor
- Ocular Therapeutix
- Start
- Aug 2019
- Primary completion
- Feb 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of dexamethasone in allergic conjunctivitis (AC), sponsored by Ocular Therapeutix. Started Aug 2019; status: completed.
02
Drugs
dexamethasone
03
Conditions
allergic conjunctivitis (AC)
Beyond the preview
Go deeper on NCT04050865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04050865.